Alder Biopharmaceuticals has dosed the first patients in proof-of-concept Phase II study evaluating the safety and efficacy of ALD403, administered monthly for the treatment of migrane.

ALD403 is an antibody therapeutic candidate being developed to target calcitonin gene-related peptide (CGRP), to treat migraine.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

"ALD403 is an antibody therapeutic candidate being developed to target calcitonin gene-related peptide (CGRP), to treat migraine."

The Montefiore Headache Center director, Albert Einstein College of Medicine professor of neurology and epidemiology and principal investigator Dr Richard Lipton said most of the currently available preventive migraine treatments are administered on a daily basis, reduce migraine frequency by 50% in only half of users and can have signifant side effects.

"A biologic targeting CGRP and offering higher rates of efficacy, along with less frequent dosing and fewer side effects, could have a tremendous benefit for patients," Lipton said.

A total of 160 patients with frequent, episodic migraines are expected to be enrolled in the double-blind, placebo-controlled study across six sites for a period of six months.

See Also:

Study particpants experienced between four and 14 migraines each month for least three months before enrolment, and take acute migraine medication.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alder Biopharmaceuticals president and chief executive officer Dr Randall Schatzman said; "The preventative approach has been welcomed by patients, evidenced by the significant patient interest at all of our trial sites, and we are proud to advance ALD403 into a proof-of-concept trial while exploring additional applications for our core technologies with therapeutic candidates in other disease areas."